PortalPublikationenCDK19 as a Potential HPV-Independent Biomarker for Recurrent...

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC

Standard

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. / Paulsen, Finn-Ole; Idel, Christian; Ribbat-Idel, Julika; Kuppler, Patrick; Klapper, Luise; Rades, Dirk; Bruchhage, Karl-Ludwig; Wollenberg, Barbara; Brägelmann, Johannes; Perner, Sven; Offermann, Anne.

in: INT J MOL SCI, Jahrgang 21, Nr. 15, 5508, 31.07.2020.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Paulsen, F-O, Idel, C, Ribbat-Idel, J, Kuppler, P, Klapper, L, Rades, D, Bruchhage, K-L, Wollenberg, B, Brägelmann, J, Perner, S & Offermann, A 2020, 'CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC', INT J MOL SCI, Jg. 21, Nr. 15, 5508. https://doi.org/10.3390/ijms21155508

APA

Paulsen, F-O., Idel, C., Ribbat-Idel, J., Kuppler, P., Klapper, L., Rades, D., Bruchhage, K-L., Wollenberg, B., Brägelmann, J., Perner, S., & Offermann, A. (2020). CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. INT J MOL SCI, 21(15), [5508]. https://doi.org/10.3390/ijms21155508

Vancouver

Paulsen F-O, Idel C, Ribbat-Idel J, Kuppler P, Klapper L, Rades D et al. CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. INT J MOL SCI. 2020 Jul 31;21(15). 5508. https://doi.org/10.3390/ijms21155508

Bibtex

@article{395ed75e5a1f4673a3bc01ae3f5a3e1f,
title = "CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC",
abstract = "The Mediator complex is a central integrator of transcription and a hub for the regulation of gene expression. Cyclin dependent kinase (CDK) 19 and its paralog CDK8 are part of its kinase domain and contribute to cancer progression in different cancer entities. STAT1 is an important immune modulator and a downstream substrate of CDK8/CDK19 mediated phosphorylation. So far, little is known about CDK19's role in head and neck squamous cell carcinoma (HNSCC) progression, its link to STAT1 activity, and related immune modulation. Immunohistochemistry for CDK19, activated pSTAT1, and PD-L1, known to be affected by STAT1, was conducted on samples of 130 primary tumors, 71 local recurrences, 32 lymph node metastases, and 25 distant metastases of HNSCC. Compared to primary tumors, CDK19 is overexpressed in local recurrences and distant metastases as well as in primary tumors that developed local recurrence after initial therapy. Patients with high-CDK19-expressing primary tumors have a significantly shorter disease-free survival. CDK19 expression correlates with pSTAT1 expression in primary tumors associated with recurrent disease, local recurrent tumors, lymph node metastases, and distant metastases. pSTAT1 expression correlates with PD-L1 expression in recurrent tumors. Our findings identify CDK19 as a potential biomarker in HNSCC to predict recurrent disease and support recent developments to target CDK19 and its paralog CDK8 in advanced cancer.",
keywords = "Biomarkers, Tumor/genetics, Cyclin-Dependent Kinases/genetics, Disease Progression, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis/genetics, Male, Mediator Complex/genetics, Neoplasm Recurrence, Local/genetics, Papillomaviridae/genetics, Papillomavirus Infections/genetics, Phosphorylation, Progression-Free Survival, Squamous Cell Carcinoma of Head and Neck/genetics",
author = "Finn-Ole Paulsen and Christian Idel and Julika Ribbat-Idel and Patrick Kuppler and Luise Klapper and Dirk Rades and Karl-Ludwig Bruchhage and Barbara Wollenberg and Johannes Br{\"a}gelmann and Sven Perner and Anne Offermann",
year = "2020",
month = jul,
day = "31",
doi = "10.3390/ijms21155508",
language = "English",
volume = "21",
journal = "INT J MOL SCI",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "15",

}

RIS

TY - JOUR

T1 - CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC

AU - Paulsen, Finn-Ole

AU - Idel, Christian

AU - Ribbat-Idel, Julika

AU - Kuppler, Patrick

AU - Klapper, Luise

AU - Rades, Dirk

AU - Bruchhage, Karl-Ludwig

AU - Wollenberg, Barbara

AU - Brägelmann, Johannes

AU - Perner, Sven

AU - Offermann, Anne

PY - 2020/7/31

Y1 - 2020/7/31

N2 - The Mediator complex is a central integrator of transcription and a hub for the regulation of gene expression. Cyclin dependent kinase (CDK) 19 and its paralog CDK8 are part of its kinase domain and contribute to cancer progression in different cancer entities. STAT1 is an important immune modulator and a downstream substrate of CDK8/CDK19 mediated phosphorylation. So far, little is known about CDK19's role in head and neck squamous cell carcinoma (HNSCC) progression, its link to STAT1 activity, and related immune modulation. Immunohistochemistry for CDK19, activated pSTAT1, and PD-L1, known to be affected by STAT1, was conducted on samples of 130 primary tumors, 71 local recurrences, 32 lymph node metastases, and 25 distant metastases of HNSCC. Compared to primary tumors, CDK19 is overexpressed in local recurrences and distant metastases as well as in primary tumors that developed local recurrence after initial therapy. Patients with high-CDK19-expressing primary tumors have a significantly shorter disease-free survival. CDK19 expression correlates with pSTAT1 expression in primary tumors associated with recurrent disease, local recurrent tumors, lymph node metastases, and distant metastases. pSTAT1 expression correlates with PD-L1 expression in recurrent tumors. Our findings identify CDK19 as a potential biomarker in HNSCC to predict recurrent disease and support recent developments to target CDK19 and its paralog CDK8 in advanced cancer.

AB - The Mediator complex is a central integrator of transcription and a hub for the regulation of gene expression. Cyclin dependent kinase (CDK) 19 and its paralog CDK8 are part of its kinase domain and contribute to cancer progression in different cancer entities. STAT1 is an important immune modulator and a downstream substrate of CDK8/CDK19 mediated phosphorylation. So far, little is known about CDK19's role in head and neck squamous cell carcinoma (HNSCC) progression, its link to STAT1 activity, and related immune modulation. Immunohistochemistry for CDK19, activated pSTAT1, and PD-L1, known to be affected by STAT1, was conducted on samples of 130 primary tumors, 71 local recurrences, 32 lymph node metastases, and 25 distant metastases of HNSCC. Compared to primary tumors, CDK19 is overexpressed in local recurrences and distant metastases as well as in primary tumors that developed local recurrence after initial therapy. Patients with high-CDK19-expressing primary tumors have a significantly shorter disease-free survival. CDK19 expression correlates with pSTAT1 expression in primary tumors associated with recurrent disease, local recurrent tumors, lymph node metastases, and distant metastases. pSTAT1 expression correlates with PD-L1 expression in recurrent tumors. Our findings identify CDK19 as a potential biomarker in HNSCC to predict recurrent disease and support recent developments to target CDK19 and its paralog CDK8 in advanced cancer.

KW - Biomarkers, Tumor/genetics

KW - Cyclin-Dependent Kinases/genetics

KW - Disease Progression

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Lymphatic Metastasis/genetics

KW - Male

KW - Mediator Complex/genetics

KW - Neoplasm Recurrence, Local/genetics

KW - Papillomaviridae/genetics

KW - Papillomavirus Infections/genetics

KW - Phosphorylation

KW - Progression-Free Survival

KW - Squamous Cell Carcinoma of Head and Neck/genetics

U2 - 10.3390/ijms21155508

DO - 10.3390/ijms21155508

M3 - SCORING: Journal article

C2 - 32752128

VL - 21

JO - INT J MOL SCI

JF - INT J MOL SCI

SN - 1661-6596

IS - 15

M1 - 5508

ER -